Fusion Protein Development Platform
Fusion proteins are proteins composed of at least two structural domains and are widely used in the pharmaceutical industry because of their unique properties. Our company has long-term devoted to the development and application of fusion protein. With years of experience, our scientists have perfected fusion protein development platform to provide comprehensive services and technical support for our global customers' rare disease therapy research and project goals.
Overview of Fusion Proteins
Fusion proteins, also known as fusion tag proteins or chimeric proteins, are proteins produced by connecting two or more genes that originally encoded different proteins. The connection methods of fusion proteins usually include chemical methods and genetic fusion. Fusion protein technology is a purposeful gene fusion and protein expression method to obtain a large number of standard fusion proteins. Using fusion protein technology, new target proteins with multiple functions can be constructed and expressed. Fusion genes can be expressed in prokaryotic cells or eukaryotic cells.
Fig.1 Fusion proteins form transcriptional hubs or onco-condensates that drive leukemogenesis. (Mittag, T., and Ansari A. Z., 2021)
Applications of Fusion Proteins
DNA vaccines are easy to produce, highly stable and low-cost. The multivalent recombinant antibody fusion protein CYF196, successfully produced through genetic engineering, is a DNA vaccine.
In the case of large enzyme molecules that can be constructed using gene fusion, the specific activity of the fusion protein enzyme is 50%-100% compared to that of a single enzyme.
By fusing drugs and specific ligands together through fusion protein technology, a protein with unique conformation and function can be formed.
Gene fusion technology can best be used to express foreign proteins in bacteria, which can improve gene expression while reducing protein degradation by host cells.
The three most important uses of fusion proteins are: as reporters of expression levels, to assist in the purification of cloned genes, and as histochemical tags to visualize proteins. With mature gene fusion technology and a chemical preparation platform, our company provides one-stop Fc fusion protein development services to support your preclinical research on rare diseases.
- Fc Fusion Protein Development
Fc fusion proteins are widely used in many preclinical research fields such as in vitro activity detection, flow cytometry, immunohistochemistry, and protein chip detection. The Fc fusions services we can provide include but are not limited to:
- Human IgG-Fc
- Mouse IgG-Fc
- Rat IgG-Fc
- Rabbit IgG-Fc
- Canine IgG-Fc
- Fusion Tags Preparation
Our company provides epitope tags, affinity tags, and fluorescent tags for protein expression, purification, and functional verification, including but not limited to:
|For use in immunological studies such as Western blotting and co-immunoprecipitation.
|His, Flag, 3xFlag, HA, Myc, Biotin, AviTag
|For protein purification or enhanced protein solubility.
|MBP, StreptAvidin, Fc, GST, SUMO, Luciferase, Protein A/G, HRP, lacZ
|For use on both live and dead cells, it is widely used in imaging studies such as cell localization and co-expression experiments.
|GFP, YFP, CFP, RFP
- Fusion Protein Characterization
Fusion protein characterization services available include but are not limited to:
- LC-MS/MS analysis
- Sequence analysis
- Purity and impurities analysis
- Post-translational modifications (PTMs)
- High-resolution molecular weight analysis (electrospray mass spectrometry)
With a research team with extensive expertise in rare disease therapy research and development, our company is confident in providing customers with fusion protein development. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Puranik, A., et al. "Development and optimization of an LC-MS based multi-attribute method (MAM) workflow for characterization of therapeutic Fc-fusion protein." Analytical Biochemistry 660 (2023): 114969.
- Mittag, T., and Ansari A. Z. "Fusion proteins form onco-condensates." Nature Structural & Molecular Biology 28.7 (2021): 543-545.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.